Cost Review Study Process Updates
Drugs Referred to Stakeholder Council
The comment period for Drugs Referred to the Stakeholder Council begins April 10, 2024. Comments are due by COB, Friday, May 10, 2024. Comments may be submitted to comments.pdab@maryland.gov with “Drugs Referred to the Stakeholder Council Comment” in the subject line.
Comments Received.
Therapeutic Alternatives
The comment period for Therapeutic Alternatives (for Drugs Referred to the Stakeholder Council) begins April 10, 2024 for the therapeutic alternatives linked below. Comments are due by COB, Friday, May 10, 2024. Comments may be submitted to comments.pdab@maryland.gov with “Therapeutic Alternatives” in the subject line.
- Biktarvy Proposed Therapeutic Alternatives
- Farxiga Proposed Therapeutic Alternatives
- Jardiance Proposed Therapeutic Alternatives
- Trulicity Proposed Therapeutic Alternatives
- Ozempic Proposed Therapeutic Alternatives
- Vyvanse Proposed Therapeutic Alternatives
The comment period for Therapeutic Alternatives for Drugs Referred to the Stakeholder Council begins April 11, 2024 for the therapeutic alternatives linked below. Comments are due by COB, Monday, May 13, 2024. Comments may be submitted to comments.pdab@maryland.gov with “Therapeutic Alternatives” in the subject line.
Additional Information
- Drugs Referred to the Stakeholder Council- Dashboard
- This is a sample database that includes non-proprietary data and data that has been approved for public display
ALL COMMENTS WILL BE POSTED AS THEY ARE RECEIVED.